Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection.
In a longitudinal investigation 103 kidney recipients were studied with respect to the development of cytomegalovirus (CMV) specific antibodies of the IgG and IgM class, in relation to the detection of CMV antigenaemia (immediate early antigen, IEA), in weekly obtained blood samples during the first 3 months after transplantation. In 15 out of 49 (31%) seronegative patients a primary infection occurred, which was characterized by a quick rise in IgM antibody followed by a slower production of IgG antibody, high maximum numbers of IEA+ cells, and a CMV syndrome in 11 patients. In 35 out of 54 (65%) seropositive patients a secondary infection occurred. After a post-operative fall in the IgG antibody, which was also found in patients without an active infection and which was accompanied by a similar drop in serum albumin and IgG, a second dip in IgG antibody was found 6 days before the first IEA+ leucocyte appeared in the blood. This was followed by a significant increase, indicative of an active immune response in consequence of the infection, 18 days later. In 31 of these 35 patients an IgM response was found. This could be ascribed to the presence of rheumatoid factor activity in 20 of them. Eight patients who showed a transient rise in IgG antibody between the two dips could be distinguished from the remaining ones by a lower maximum number of IEA+ cells and less severe disease symptoms. The described results suggest that (i) an adequate humoral immune system may prevent symptomatic CMV disease in secondary infections; and (ii) CMV-specific antibodies may be removed from the circulation by antigens present in infected tissues before CMV antigenaemia becomes detectable.
Van der Giessen
M
M
Department of Clinical Immunology, University Hospital, Groningen, The Netherlands.
van den Berg
A P
AP
van der Bij
W
W
Postma
S
S
van Son
W J
WJ
The
T H
TH
D000914:Antibodies, Viral / Q000032:analysis*; D000918:Antibody Specificity; D000954:Antigens, Surface / Q000097:blood; D000956:Antigens, Viral / Q000097:blood*; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology*; D006801:Humans; D017874:Immediate-Early Proteins; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D016030:Kidney Transplantation / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000097:blood
D000914:Antibodies, Viral; D000954:Antigens, Surface; D000956:Antigens, Viral; D017874:Immediate-Early Proteins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D014763:Viral Matrix Proteins; C044582:immediate-early proteins, cytomegalovirus